Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cel-Sci Corporation Common Stock (NY:CVM)

0.2118 +0.0129 (+6.49%)
Streaming Delayed Price Updated: 2:54 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,683,447
Open 0.1900
Bid (Size) 0.2161 (8)
Ask (Size) 0.2297 (4)
Prev. Close 0.1989
Today's Range 0.1831 - 0.2175
52wk Range 0.1814 - 2.390
Shares Outstanding 77,211,541
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Closing of $2.5 Million Offering
From CEL-SCI Corporation
Via Business Wire

Performance

YTD
-49.0%
-49.0%
1 Month
-35.6%
-35.6%
3 Month
-49.0%
-49.0%
6 Month
-80.6%
-80.6%
1 Year
-88.6%
-88.6%

More News

Read More
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CEL-SCI Announces Pricing of $2.5 Million Offering
From CEL-SCI Corporation
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
From CEL-SCI Corporation
Via Business Wire
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
From CEL-SCI Corporation
Via Business Wire
Stay updated with the stocks that are on the move in today's pre-market session.
Via Chartmill
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Closing of $5 Million Offering
From CEL-SCI Corporation
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November
Via Benzinga
Crude Oil Gains 1%; Chicago PMI Falls In December
Via Benzinga
Exposures Fossil Fuels
US Stocks Open Lower; Dow Tumbles 600 Points
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Cel-Sci Shares Premarket On Monday?
Via Benzinga
US Stock Futures Slip After Friday's Fall: 'Santa Rally' In Doubt? Analyst Calls It A Bit Of Profit-Taking
Via Benzinga
Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Via Benzinga
CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday
Via Benzinga
CEL-SCI Announces Pricing of $5 Million Public Offering
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Proposed Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
From CEL-SCI Corporation
Via Business Wire
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
From CEL-SCI Corporation
Via Business Wire
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
From CEL-SCI Corporation
Via Business Wire

Frequently Asked Questions

Is Cel-Sci Corporation Common Stock publicly traded?
Yes, Cel-Sci Corporation Common Stock is publicly traded.
What exchange does Cel-Sci Corporation Common Stock trade on?
Cel-Sci Corporation Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Cel-Sci Corporation Common Stock?
The ticker symbol for Cel-Sci Corporation Common Stock is CVM on the New York Stock Exchange
What is the current price of Cel-Sci Corporation Common Stock?
The current price of Cel-Sci Corporation Common Stock is 0.2118
When was Cel-Sci Corporation Common Stock last traded?
The last trade of Cel-Sci Corporation Common Stock was at 04/04/25 02:54 PM ET
What is the market capitalization of Cel-Sci Corporation Common Stock?
The market capitalization of Cel-Sci Corporation Common Stock is 16.35M
How many shares of Cel-Sci Corporation Common Stock are outstanding?
Cel-Sci Corporation Common Stock has 16M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.